| Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade BC Miller, DR Sen, R Al Abosy, K Bi, YV Virkud, MW LaFleur, KB Yates, ... Nature immunology 20 (3), 326-336, 2019 | 1645 | 2019 |
| PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance CL Tan, JR Kuchroo, PT Sage, D Liang, LM Francisco, J Buck, YR Thaker, ... Journal of Experimental Medicine 218 (1), 2021 | 227 | 2021 |
| Lack of TIM-3 immunoregulation in multiple sclerosis L Yang, DE Anderson, J Kuchroo, DA Hafler The Journal of Immunology 180 (7), 4409-4414, 2008 | 161 | 2008 |
| Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment KE Pauken, O Shahid, KA Lagattuta, KM Mahuron, JM Luber, MM Lowe, ... Journal of Experimental Medicine 218 (4), 2021 | 92 | 2021 |
| B-cell-specific checkpoint molecules that regulate anti-tumour immunity L Bod, YC Kye, J Shi, E Torlai Triglia, A Schnell, J Fessler, SM Ostrowski, ... Nature 619 (7969), 348-356, 2023 | 75 | 2023 |
| PD-L1–PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection JA Perry, L Shallberg, JT Clark, JA Gullicksrud, JH DeLong, BB Douglas, ... Nature immunology 23 (5), 743-756, 2022 | 67 | 2022 |
| Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer LL Thompson, NA Krasnow, MS Chang, J Yoon, EB Li, NJ Polyakov, ... JAMA dermatology 157 (5), 577-582, 2021 | 49 | 2021 |
| The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity JR Kuchroo, DA Hafler, AH Sharpe, LE Lucca Science immunology 6 (65), eabf4034, 2021 | 32 | 2021 |
| Severity of innate immune-mediated colitis is controlled by the cytokine deficiency-induced colitis susceptibility-1 (Cdcs1) locus J Ermann, WS Garrett, J Kuchroo, K Rourida, JN Glickman, A Bleich, ... Proceedings of the National Academy of Sciences 108 (17), 7137-7141, 2011 | 32 | 2011 |
| Author correction: subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade BC Miller, DR Sen, R Al Abosy, K Bi, YV Virkud, MW LaFleur, KB Yates, ... Nature immunology 20 (11), 1556, 2019 | 26 | 2019 |
| Effect of dermatological consultation on survival in patients with checkpoint inhibitor‐associated cutaneous toxicity LL Thompson, EB Li, NA Krasnow, MS Chang, JT Said, GE Molina, ... British Journal of Dermatology 185 (3), 627-635, 2021 | 18 | 2021 |
| Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors LL Thompson, MS Chang, NJ Polyakov, AE Blum, N Josephs, ... Journal of the American Academy of Dermatology 86 (4), 886-889, 2022 | 8 | 2022 |
| CD8+ T cell-independent mechanisms of PD-1-mediated suppression of anti-tumor immunity in mice KE Pauken, V Juneja, K McGuire, M LaFleur, J Kuchroo, P Sage, ... The Journal of Immunology 198 (1_Supplement), 205.11-205.11, 2017 | 3 | 2017 |
| Single-cell analyses characterize circulating anti-tumor CD8+ T cells in mice and humans and identify markers for their enrichment KE Pauken, O Shahid, KA Lagattuta, KM Mahuron, JM Luber, MM Lowe, ... The Journal of Immunology 206 (1_Supplement), 26.02-26.02, 2021 | 1 | 2021 |
| PD-1 restricts the development and effector function of tissue regulatory T cells in experimental autoimmune encephalomyelitis D Liang, J Judge, S Markson, S Guinn, JL Collier, O Shahid, S Manne, ... The Journal of Immunology 208 (1_Supplement), 163.01-163.01, 2022 | | 2022 |
| Impact of systemic corticosteroids for cutaneous immune-related adverse events on survival outcomes in patients with advanced cancer: A retrospective cohort study. J Yoon, LL Thompson, NA Krasnow, M Chang, E Li, D McMahon, ... Journal of Clinical Oncology 39 (15_suppl), e14523-e14523, 2021 | | 2021 |
| Abstract PO016: Single-cell analyses characterize circulating anti-tumor CD8 T cells and identify markers for their isolation KE Pauken, O Shahid, KA Lagattuta, KM Mahuron, JM Luber, MM Lowe, ... Cancer Immunology Research 9 (2_Supplement), PO016-PO016, 2021 | | 2021 |
| PD-1 blockade later but not at post-transplant attenuates chronic graft-versus-host disease S Rhee, EG Aguilar, K Paz, R Flynn, J Kuchroo, P Sage, AH Sharpe, ... The Journal of Immunology 204 (1_Supplement), 87.8-87.8, 2020 | | 2020 |
| Abstract PR9: Loss of PD-1 promotes antitumor immunity by improving functions of both PD-1+ and PD-1-CD8+ T cells in the tumor microenvironment KE Pauken, VR Juneja, A Ringel, JH Rowe, KP Burke, PT Sage, ... Cancer Immunology Research 8 (3_Supplement), PR9-PR9, 2020 | | 2020 |
| Loss of PD-1 promotes antitumor immunity by improving functions of both PD-1+ and PD-1-CD8+ T cells in the tumor microenvironment. KE Pauken, VR Juneja, A Ringel, JH Rowe, KP Burke, PT Sage, ... CANCER IMMUNOLOGY RESEARCH 8 (3), 127-127, 2020 | | 2020 |
